Genomma Lab InternacionalB de CVMEX:LABB +2.59%66 Return-on-Tangible-Equity is 34.34% as of Mar. 2026, which is 8% above its 10-year median of 31.89. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 899 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 86.54% on this metric.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity or its related term are showing as below:
MEX:LABB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -99.95 Med: 31.89 Max: 83.32
Current: 28.64
During the past 13 years, Genomma Lab InternacionalB de CV's highest Return-on-Tangible-Equity was 83.32%. The lowest was -99.95%. And the median was 31.89%.
MEX:LABB's Return-on-Tangible-Equity is ranked better than 86.54% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.68
vs MEX:LABB: 28.64
Genomma Lab InternacionalB de CV (MEX:LABB) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Related Terms
Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Chart
MEX:LABB vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 34.34% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Return-on-Tangible-Equity of 34.34% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 31.89. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #121 out of 899 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity too high?
Genomma Lab InternacionalB de CV's current Return-on-Tangible-Equity of 34.34% is near median its 10-year median of 31.89. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.68. Genomma Lab InternacionalB de CV's value of 34.34% is 347.1% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #121 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #121 out of 899 companies for Return-on-Tangible-Equity. This places Genomma Lab InternacionalB de CV in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.68. Genomma Lab InternacionalB de CV's value of 34.34% is 347.1% above this benchmark. While the company's 10-year median is 31.89 vs. the industry median of 7.68, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.68, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Return-on-Tangible-Equity of 34.34% is 347.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Return-on-Tangible-Equity is 34.34%, which is near median its own 10-year median of 31.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Return-on-Tangible-Equity is 34.34%, which is near median its 10-year median of 31.89 and 347.1% above the Drug Manufacturers industry median of 7.68. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Return-on-Tangible-Equity is 34.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Return-on-Tangible-Equity: 34.34% (near median its 10-year median of 31.89)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 347.1% above the Drug Manufacturers median (#121 of 899)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
